Stocktoria

Aldeyra Therapeutics, Inc. ALDX

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2014-05-02 · LEI

Aldeyra Therapeutics, Inc. statistics & valuation

Market cap$110.4M
P / B2.5×
Return on equity-76.5%
Net cash$54.7M
Enterprise value USD$55.6M
Earnings yield EBIT/EV-63.4%
Return on capital-79.7%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
2016201720182019202020212022202320242025
Operating margin (%)
2016201720182019202020212022202320242025
Return on equity (%)
-86.40% -56.40% -44.90% -126.50% -63.10% -28.10% -41.10% -31.30% -78.70% -76.50% 2016201720182019202020212022202320242025
Shares outstanding
12.6M 19.1M 26.2M 28.7M 38.7M 58.1M 58.6M 59.2M 59.6M 60.2M 2016201720182019202020212022202320242025
Net debt ($)
-$10.6M -$18.6M -$31.3M -$28.4M -$61.8M -$213.7M -$128.1M $15.3M -$39.2M -$54.7M 2016201720182019202020212022202320242025
Share buybacks ($)
2016201720182019202020212022202320242025
Return on assets (%)
-74.20% -50.60% -40.90% -80.50% -45.10% -24.80% -34.20% -25.30% -53.40% -47.00% 2016201720182019202020212022202320242025
Free cash flow margin (%)
2016201720182019202020212022202320242025
Debt / equity (×)
0.06× 0.04× 0.19× 0.33× 0.27× 0.08× 0.11× 0.13× 0.22× 0.35× 2016201720182019202020212022202320242025
EPS ($)
-$1.07 -$1.06 -$0.64 -$0.94 -$0.56 2016201720182019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Return on assets-47.0%-53.4%-25.3%-34.2%-24.8%-45.1%-80.5%-40.9%-50.6%-74.2%
Return on equity-76.5%-78.7%-31.3%-41.1%-28.1%-63.1%-126.5%-44.9%-56.4%-86.4%
Debt / equity0.35×0.22×0.13×0.11×0.08×0.27×0.33×0.19×0.04×0.06×
Current ratio2.585.596.6411.7819.776.695.8211.1813.1110.93

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.